BKG Pharma is a privately held Danish biopharmaceutical company exclusively committed to discovery, development and commercialization of novel antibiotics to treat multidrug-resistant infections. 

The company was founded in 2004 by CEO and inventor MD Birgit K. Giwercman who has an extensive scientific and industrial background in infectious diseases and drug development.

BKG Pharma has laboratory facilities in Copenhagen where essential in vitro research is carried out but is predominantly run as a virtual drug development company with a core team of experts overseeing the outsourcing of research and development to a large network of CROs, academics and consultants.

Chairman LL.M. Rasmus H. Schmiegelow has more than 15 years M&A, venture capital and transaction experience and has participated in more than fifty transactions on five continents. Cross-border transactional work includes licensing agreements, joint ventures and strategic alliances to facilitate international growth of large corporations and small high growth start-ups.